drugset / Trial / NCT04895059

Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components

NCT04895059

Phase 1 Completed 36 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedCrossoverOpen-labelTreatment

Summary

Monocentric study of no pharmacokinetic interaction between rosuvastatin 20 mg and ezetimibe 10 mg. An open design, randomized, single dose with three periods, six sequences and crossed, in healthy volunteers with fasting conditions, managed in fixed dose combination (Sponsor Laboratorios Silanes S.A. de C.V.) versus individual components managed by separated (Crestor®, product of Astrazeneca, S.A. de C.V and Ezetrol®. product of Undra S.A. de C.V.)

Timeline

Start
2017-04-30
Primary completion
2018-01-15
Completion
2018-01-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ezetimibe Unknown 10 mg Oral
Comparator Rosuvastatin Small molecule 20 mg Oral

Indications

No indication recorded.